Company / Financials
PALVELLA THERAPEUTICS, INC. Financials
FY2013-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
-
FY2024
Net Income
-$17.4M
FY2024 · -193.3% YoY
Profit Margin
-
FY2024 · net income / revenue
ROE
-27.9%
FY2024 · return on equity
Total Assets
$88.2M
FY2024
Total Debt
-
FY2024
Equity
$62.6M
FY2024
ROA
-19.8%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations-Net Income HistoryProfit after all expenses and taxes-$17.4M-193.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$14.1M-18.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$5.9M+93.2% YoYR&D Expense HistoryResearch and development spending$8.2M-7.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$430.0KIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$7.83-1640.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$7.83Shares Outstanding HistoryWeighted average diluted shares outstanding2.2M-97.0% YoY